Company snapshot
Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from 10,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe.
In February 2012 SCENESSE® was filed for review by the European Medicines Agency for EPP. A confirmatory six month Phase III US EPP trial commenced in May 2012. Presently, there is no known effective treatment for EPP and SCENESSE® has been granted orphan drug status. Based in Melbourne, Australia, Clinuvel has operations in Europe and the US.
|
|
|
|
|
Facts |
ASX Listed Shares on Issue Options (unlisted) Conditional performance rights Top 50 own 52 weeks price range Market cap (3/12/2012) Employees (FTE) |
2001 34,651,874 35,000 2,161,779 67.8% $1.44 - $2.31 A$65.59m 22 |
|
Locations |
Melbourne, Australia Baar, Switzerland New York, USA |
Company headquarters European operational office US operational office |
|
Stock listings |
ASX Xetra-DAX Level 1 ADR |
CUV UR9 CLVLY |
|
Finances |
Cash/assets at bank (30/09/2012) Monthly spend rate (av. Q4 '11 - Q3 ’12) |
A$11.453m A$0.823m |
|
Products |
SCENESSE® (afamelanotide 16mg implant)
|
First-in-class photoprotective and repigmentation drug currently in US Phase II and III trials, EMA marketing authorisation application under review Alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue in early development |
|
People |
Chair CEO, Director Non-Executive Director Non-Executive Director Non-Executive Director Acting Chief Scientific Officer CFO, Company Secretary |
|
|
Contact |
General Investors |
This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last updated: December 3, 2012
